DIL Dyadic International

Dyadic International, Inc. (AMEX:DIL), a biotechnology company engaged in the development, manufacture and sale of biological products, announced today that its President and CEO, Mark Emalfarb, will present at the BIO CEO and Investor Conference, to be held on February 13-15, 2006 at The Waldorf Astoria Hotel in New York City. The presentation will take place in the Empire Room at 11:30 AM EST on Tuesday, February 14, 2006. Presentation slides will be available on the Dyadic website at http://www.dyadic-group.com. The 2006 Biotechnology Industry Organization CEO & Investor Conference will highlight commercial advances in bioethanol. Dyadic has devoted significant R&D resources over the last decade towards developing its C1 Host Technology and other proprietary technologies to produce cellulases and other important enzymes that convert cellulosic substrates such as corn stover and sugar cane bagasse into glucose from which bioethanol can be produced, and which are therefore expected by Dyadic to have direct applicability to the bioethanol segment of the industry. For additional information, please also see the Biotechnology Industry Organization press release entitled "BIO CEO and Investor Conference to Highlight Commercial Advances in Bioethanol," available at http://www.bio.org/news/newsitem.asp?id=2006_0201_02. Neither BIO's press release nor any information on its website is incorporated by reference in this press release. The conference, now in its 8th year, is designed to educate new investors and media on the value, risks and rewards offered by the industry and to fuel continued industry growth and investments in 2006. Complimentary registration is open to qualified investors and members of the media at http://www.ceo.bio.org. About Dyadic Dyadic International, Inc., is engaged in the development, manufacture and sale of proteins, enzymes and other bio-molecules, as well as the licensing of its enabling proprietary technology to collaborators for the discovery, development and manufacture of biological products from genes. Dyadic markets its products and services for applications in the textile, chemical, agricultural, pulp & paper, pharmaceutical, biotechnology and other industries, using its proprietary C1 Host Technology and C1 Expression and Screening Systems for the discovery, development and production of biological products. Cautionary Statement for Forward-Looking Statements Certain statements contained in this press release are "forward-looking statements." These forward-looking statements involve risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of these risks and uncertainties, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2004, and our Quarterly Report on Form 10-QSB for the quarter ended September 30, 2005. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements.